Abstract:Background. The discovery of the presence of fetal genetic material in maternal blood has opened up a new approach to prenatal diagnosis. One approach that has been extensively investigated over the past few decades is the isolation of fetal cells from maternal blood (Herzenberg et al. Proc Natl Acad Sci USA. 1979;76:1453-5; Bianchi et al. Proc Natl Acad Sci USA. 1990;87:3279-83; Cha et al. Prenat Diagn. 2005-25:586-91). As the fetal cells are scarce and the enrichment is of low efficiency, the technique could not be implemented in clinics. In 1997, Lo et al. (Lancet 1997-350(9076):485-7) discovered that cell-free fetal DNA is present in the plasma and serum of pregnant women. This discovery suggests that maternal plasma/serum DNA may be a useful source of material for non-invasive prenatal diagnosis. The objective of our study was to investigate the feasibility of using fetal DNA in maternal plasma for prenatal diagnosis. Methods. Plasma DNA in 277 blood samples of 40 pregnant women at the gestational period from 5 to 40 weeks and 24 h after delivery were extracted by column separation. FQ-PCR was used to amplify the SRY sequence in 237 plasma samples of 30 pregnant women. Fluorescent PCR was used to amplify 9 short tandem repeat loci simultaneously in 40 plasma samples of 10 pregnant women, and genomic DNA samples from their husbands were amplified by the same method. Results. The fetal SRY sequence could be detected from the 7th week of gestation, with a concentration that increased with progressing gestational age, attaining its highest peak before delivery. Twenty-four hours after delivery, fetal SRY sequence could not be detected in the maternal plasma. The concordance rate of the SRY sequence amplification results of plasma-free DNA, with real fetal gender was 100%. Analysis of maternal plasma samples collected during pregnancy revealed the presence of paternally inherited fetal-specific alleles. Among the 30 collected plasma samples, fetal-specific alleles were detected in 23 plasma DNA samples. The rate of positive results was 76% (23/30), and the frequency of positive results was 6/10 in early pregnancy, 8/10 in middle pregnancy, and 9/10 in late pregnancy. Short tandem repeats could not be detected from the maternal plasma 24 h after delivery. Conclusion. Fluorescent PCR can be used for amplification of fetal SRY sequence and STRs in maternal plasma to obtain fetal genetic information, which may have implications for non-invasive prenatal diagnosis of certain hereditary diseases.

[Sensitivity and Specificity of Noninvasive Prenatal Fetal RhD Genotesting: a Meta-Analysis].

Quantitative Analysis of Fetal RhD Genotyping with Fetal DNA from RhD-negative Maternal Plasma

Noninvasive screening of fetal RHD genotype in Chinese pregnant women with serologic RhD-negative phenotype.

Prenatal Determination of Fetal RhD Genotype by Real-Time PCR Examination of Fetal DNA in Maternal Plasma

Non-Invasive Foetal Rhd Genotyping Via Real-Time Pcr of Foetal Dna from Chinese Rhd-Negative Maternal Plasma

Clinical performance of cell free DNA for fetal RhD detection in RhD-negative pregnant individuals from the US population.

Diagnosis and therapy of Rh(D) hemolytic diseases caused by maternal-fetal blood group incompatibility.

Comparison of Three Methods for the Gene Analysis of Fetal Cells from Maternal Peripheral Blood.

Antenatal RHD screening to guide antenatal anti-D immunoprophylaxis in non-immunized D- pregnant women

Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis

Enrichment of circulating fetal nucleated red blood cell for non-invasive prenatal diagnosis with a new polyclonal antibody specific to fetal hemoglobin

Noninvasive fetal genotyping of single nucleotide variants and linkage analysis for prenatal diagnosis of monogenic disorders

Real‐world performance of a clinical droplet digital polymerase chain reaction assay for non‐invasive foetal blood group and platelet antigen genotyping of alloimmunized pregnant women with antibodies directed against RhD, RhE, Rhc, RhC, K1, HPA‐1a or HPA‐5b: A 1‐year experience

Detection of fetal RHD genotyping with fetal DNA from RhD-negative maternal plasma

Examination of Fetal Sex in the Peripheral Blood of Pregnant Women before 9 Completed Weeks' Gestation

Feasibility Study of Using Fetal DNA in Maternal Plasma for Non‐invasive Prenatal Diagnosis

Analysis of Perinatal Outcomes in Sensitized Pregnant Women with RhD-negative Blood Type without Passive Immunotherapy

Recent progress in non-invasive prenatal diagnosis.

Identification of pregnant women with DFR genotype and discussion of prenatal examination strategy

Diagnosis of fetal chromosomal aneuploidy by free fetal DNA in maternal plasma in the first trimester

Evaluation of prenatal screening for fetal chromosomal aneuploidies by non-invasive fetal cell-free DNA test